Abstract: The invention disclosed provides means of inhibiting, ameliorating, and/or treatment of rheumatoid arthritis through the use of Noble gas containing mixtures. In one embodiment, the invention provides means of reducing inflammation and immune associated pathology through administration of Noble gas mixtures. In one specific embodiment, Xenon gas is administered to a patient in need at concentrations and frequencies sufficient to inhibit inflammatory and autoimmune processes. In another embodiment Noble gas mixtures are administered to reduce pain and provide symptomatic relieve to a patient suffering from rheumatoid arthritis. In another embodiment the use of Noble gas containing mixtures is disclosed as a means of reducing joint destruction through inhibition of matrix metalloprotease production and activity.

Abstract: Methods and compositions related to promoting hair growth are described.

Abstract: The invention provides a solution to the drawbacks associated with conventional alginate dressings. This invention features improved alginate dressings or bandages as well as a fabrication process that results in an alginate sheet that is preloaded with drug, can be stored in a freeze-dried state, and is compliant and ready to use at the time of administration.

Abstract: Formulations having, as active agents, at least one quaternized polymeric microgel and at least one nonionic surfactant, methods of making, and methods of using are described.

Abstract: A pesticide for the extermination of an insect of the order Blattodea, and particularly of Blattella germanica, the pesticide comprising a uniform mixture of: a Blattella germanica attractant comprising about 75% cooked mashed potatoes and about 14% cooked eggs yolk; and an active ingredient comprising boric acid in a concentration of about 10%, thereby providing a non-toxic to humans or pets pesticide which attracts the insect, and upon consuming it by the insect, the active ingredient exterminates the insect.

Abstract: A hard or soft capsule is disclosed comprising a shell and a fill material, wherein the shell comprises an interpenetrating network comprising a silk polymer and a film-forming natural polymer. A method of making a hard or soft capsule is also disclosed, comprising dissolving a silk protein in a solvent system to form a solubilized silk protein solution; mixing the solubilized silk protein solution with a film-forming natural polymer to form a homogenous shell material; and encapsulating a fill material with the homogenous shell material.

Abstract: The present invention provides methods and compositions for treating bladder cancer, including metastatic bladder cancer and non-muscle-invasive bladder cancer, by administering a composition comprising nanoparticles that comprise mTOR inhibitor and optionally an albumin.

Abstract: The present invention provides a pharmaceutical composition in a powder form for providing wound protection, hemostasis, or anti-adhesion in the gastrointestinal tract, which comprises a certain mucoadhesive polymer; and a certain hygroscopic agent.

Abstract: The present application relates to encapsulates, compositions, products comprising such encapsulates, and processes for making and using such encapsulates. Such encapsulates comprise a core comprising a perfume and a shell that encapsulates said core, such encapsulates may optionally comprise a parametric balancing agent, such shell comprising one or more azobenzene moieties.

Abstract: The invention is directed to a cosmetic composition and the precursor thereof. The composition has solid agent and liquid agent, both of which are cosmetic benefit ingredients. The solubility of solid agents in liquid agents in the inventive compositions is enhanced in the presence of a tricyclodecane amide.

Abstract: An intra-articular pharmaceutical composition is used for the treatment and/or the prevention of acute or chronic osteoarticular diseases and acute or chronic osteoarticular symptoms especially osteoarthritis. The composition includes a possibly adequate pharmaceutical carrier or diluent, a glycosaminoglycan, a compound activating the alpha 2 adrenergic receptor, an anti-inflammatory agent and stem cells.

Abstract: Effective treatments of pain for extended periods of time are provided. Through the administration of an effective amount of clonidine in a fiber at or near a target site, one can relieve pain caused by diverse sources, including but not limited to spinal disc herniation (i.e. sciatica), spondilothesis, stenosis, discogenic back pain and joint pain, as well as pain that is incidental to surgery. When appropriate fiber formulations are provided within biodegradable polymers, this pain relief can be continued for at least three days.

Abstract: Provided is a triblock copolymer represented by General Formula (I): CNR-PEG-CNR??(1) or a polycation thereof, wherein each CNR is independently a polymer segment having a repeating unit containing as part of a pendant group a cyclic nitroxide radical that binds to the polymer main chain via a linking group having at least one imino group or ether bond, and PEG is a segment containing poly(ethylene glycol).

Abstract: The invention provides a gel-form hair cosmetic composition, which contains components (a) to (c) emulsified in an aqueous component, and which exhibits an endothermic peak temperature of from 40° C. to 75° C. as measured through DSC, wherein the components are (a) a polyalkyleneimine derivative or a salt thereof, the polyalkyleneimine derivative being formed of a polyalkyleneimine having a weight average molecular weight of from 3,300 to 50,000, in which one of the substituents of R1—CO—, R2—(CH2)n—CHX—CH2—, and R3—NH—CO— [R1 is H, alkyl, alkenyl, or the like; R2 is H, alkyl, alkoxy, alkenyl or the like; n is 0 or 1; X is H or OH; R3 is H, alkyl, or alkenyl; at least one of R1 to R3 has 13 or more carbon atoms; and the entirety of R1, R2, and R3 has an average number of carbon atoms of 9 or more and a linear group content of 30 mol % or more] is bonded to 40 mol % or more of the nitrogen atoms of the polyalkyleneimine; (b) a C12 to C28 saturated aliphatic alcohol; and (c) a cationic surfactant.

Abstract: The invention relates to aqueous suspension pharmaceutical compositions of poorly water soluble drugs, wherein said drugs are selected from compounds of formula (I) (Formula (I)), wherein R1-R9 are defined herein; processes for preparing these compositions and their use in medicine, especially their use in the treatment of ocular diseases.

Abstract: Formulations having, as active agents, at least one quaternized polymeric microgel and at least one surfactant, methods of making, and methods of using are described.

Abstract: The present invention is directed to immediate release film coating compositions for use on oral dosage forms such as compressed tablets and other orally-ingestible substrates which contain medium chain glycerides as detackifiers. The film coating compositions can be applied either directly to a substrate or after the substrate has been coated with a subcoat. In preferred aspects, the polymer is polyvinyl alcohol and the medium chain glycerides are mixtures of caprylic (8 carbon chain) and capric (10 carbon chain) mono- and diesters of glycerin. Aqueous suspensions comprising the inventive film coating compositions, methods of applying the coatings to substrates and the coated substrates themselves are also disclosed.

Abstract: Described is a storage-stable dust-free homogeneous particulate formulation. The formulation consists of (a) at least one water-soluble Vitamin E-derivative, (b) at least one hydrophilic polymer, (c) optionally additional surface-active substances, and (d) optionally additional pharmaceutical additives. The sum of (a), (b), (c) and (d) equals 100% by weight of the formulation. The fines fraction with particle diameters of less than 100 ?m is less than 10% by weight. Describe also is a process for manufacturing the formulation, and use of the formulation as a solubilizing composition in pharmaceutical formulations.

Abstract: The present invention is an orally consumed fixed combination formulation of both rosuvastatin and ezetimibe in one tablet that is expected to have the same Area Under Curve as two active ingredients taken together individually orally, and pharmaceutically acceptable additives suitable for the preparation. In preferred embodiments of this invention, the rosuvastatin is in the form of rosuvastatin calcium and the pharmaceutically acceptable additives are selected from diluents, disintegrants, glidants, lubricants, colorants and combinations thereof.

Abstract: The invention provides a multi-layered pharmaceutical composition comprising two or more formulations with varying properties. In some embodiments, the pharmaceutical compositions provide combinations of different organoleptic properties within the same product. In certain embodiment, these combinations allow for a modified release profile of active ingredients as the user enjoys the pharmaceutical composition. The invention further provides methods for making and using the pharmaceutical composition.